Optomed ’s financial reporting in 2020

Report this content

Optomed Plc     Stock Exchange Release             20 December 2019 At 1 p.m, Helsinki

Optomed’s financial reporting in 2020

Optomed Plc will release its Financial Statement Bulletin, Half-Year Financial Report and Interim Reports in 2020 as follows:

  • Financial Statement Bulletin for 1 January – 31 December 2019, 28 February 2020
  • Interim Report for 1 January – 31 March 2020, 29 May 2020
  • Half-Year Financial Report for 1 January – 30 June 2020, 27 August 2020
  • Interim Report for 1 January – 30 September 2020, 25 November 2020

Annual Report 2019, which includes the company’s financial statements, the report of the Board of Directors, the corporate governance statement and the remuneration report, will be published during the week starting on 16 March at the latest.

Optomed’s Annual General Meeting is planned to be held on 28 April 2020 in the Helsinki region, Finland. The Board of Directors will convene the meeting separately at a later date.

A shareholder who requests a certain issue belonging to the General Meeting to be included on the agenda of the meeting, is asked to notify the Board of Directors in writing by post Optomed Plc, Yrttipellontie 1, FI-90230 Oulu, Finland no later than 17 January 2020.

Optomed Plc

Further enquiries

Lars Lindqvist, CFO, Optomed Plc, lars.lindqvist@optomed.com

Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com


Nasdaq Helsinki Ltd

Principal media


Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 52 international patents protecting the technology. In 2018, Optomed’s revenue reached EUR 12.7 million and pro forma revenue with the acquisition of Commit; Oy amounted to EUR 14.5 million. At the end of September 2019, Optomed employed 105 professionals.